| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 26S proteasome non-ATPase regulatory subunit 4, 26S proteasome regulatory subunit RPN10, 26S proteasome regulatory subunit S5A, Antisecretory factor 1, AF, ASF, Multiubiquitin chain-binding protein, PSMD4, MCB1 |
| Entrez GeneID | 5710 |
| WB Predicted band size | 40.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This PSMD4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 300-328 amino acids from the C-terminal region of human PSMD4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于PSMD4抗体的3篇参考文献摘要(基于公开研究主题模拟，非真实文献)：
---
1. **"PSMD4 as a critical component of the 26S proteasome assembly"**
*作者：Chen L, et al.*
摘要：研究揭示了PSMD4在26S蛋白酶体组装中的关键作用，通过敲除实验表明其缺失会破坏蛋白酶体稳定性，并利用特异性抗体验证了其在多种细胞系中的表达模式。
2. **"Overexpression of PSMD4 promotes tumor progression via NF-κB activation"**
*作者：Wang Y, et al.*
摘要：该文献发现PSMD4在结直肠癌中高表达，并通过抗体验证其与NF-κB信号通路的相互作用，提示其作为癌症治疗靶点的潜力。
3. **"A novel monoclonal antibody against PSMD4 for detecting proteasome dysfunction in neurodegenerative diseases"**
*作者：Smith J, et al.*
摘要：开发了一种高特异性抗PSMD4的单克隆抗体，证实其在阿尔茨海默病模型脑组织样本中检测蛋白酶体功能障碍的实用性，为疾病机制研究提供工具。
---
*注：以上内容为模拟示例，实际文献需通过PubMed或学术数据库检索。如需真实文献，建议使用关键词“PSMD4 antibody”或“PSMD4 proteasome”在Google Scholar查询。*
The PSMD4 antibody targets the 26S proteasome non-ATPase regulatory subunit 4 (PSMD4), a critical component of the 19S regulatory particle within the 26S proteasome complex. The proteasome is responsible for degrading ubiquitinated proteins, regulating cellular processes like cell cycle progression, DNA repair, and stress responses. PSMD4. also known as ASB7 or S5a, plays a key role in recognizing polyubiquitinated substrates via its ubiquitin-interacting motifs (UIMs), facilitating their translocation to the proteolytic core. Dysregulation of PSMD4 has been implicated in cancer, neurodegenerative diseases, and immune disorders, making it a research focus for therapeutic targeting.
PSMD4 antibodies are widely used in biomedical research to study proteasome dynamics, protein degradation pathways, and disease mechanisms. They enable detection of PSMD4 expression levels through techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). Specific monoclonal or polyclonal variants are developed to ensure high specificity across human, mouse, or rat samples. Validated antibodies are essential for experiments exploring PSMD4’s interaction with ubiquitin chains or its role in diseases like multiple myeloma or Alzheimer’s. Researchers also utilize these antibodies to assess proteasome inhibition efficacy in drug development. Proper validation via knockout controls or peptide blocking is recommended to confirm antibody reliability.
×
